Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20876038 | 0.81 | SLC6A2 (0.47) | CYP3A4CYP1A2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6157911 | 0.79 | SLC6A2 (0.45) | CYP3A4CYP1A2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL4954290 | 0.79 | SLC6A2 (0.45) | CYP3A4CYP1A2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL225565 | 0.78 | SLC6A3 (0.48) | CYP3A4CYP1A2SLC6A3SLC6A2SLC6A4 | |
| Formamide SCHEMBL28321660 | 0.78 | CYP3A4 (0.49) | CYP3A4CYP1A2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL17732794 | 0.78 | SLC6A2 (0.44) | CYP3A4CYP1A2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL17732800 | 0.78 | SLC6A2 (0.44) | CYP3A4CYP1A2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL243460 | 0.76 | — | — | |
| SCHEMBL17603147 | 0.76 | — | — | |
| SCHEMBL11877966 | 0.75 | KDM4E (0.49) | CYP3A4CYP1A2SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113073346-B | Electrochemical method for simultaneously preparing o-diol and pyrrole methoxylation products | 万华化学集团股份有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-113073346-A | Electrochemical method for simultaneously preparing o-diol and pyrrole methoxylation products | 万华化学集团股份有限公司 | 2021-07-06 | — | — | CN | claimed |
| CN-118255685-A | Tricyclic compound, pharmaceutical composition and application thereof | 珂阑(上海)医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-113073346-B | Electrochemical method for simultaneously preparing o-diol and pyrrole methoxylation products | 万华化学集团股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-113456634-A | Pyrrolopyrrole compositions as Pyruvate Kinase (PKR) activators | 福马治疗股份有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-109311897-B | Pyrrolopyrrole compositions as Pyruvate Kinase (PKR) activators | 福马治疗股份有限公司 | 2021-07-20 | — | — | CN | disclosed |
| CN-113073346-A | Electrochemical method for simultaneously preparing o-diol and pyrrole methoxylation products | 万华化学集团股份有限公司 | 2021-07-06 | — | — | CN | disclosed |
| EP-3148963-B1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-06-13 | — | — | EP | disclosed |
| US-8859814-B2 | Alpha-substituted N-sulfonyl gylcine amides antagonists of CCR10, compositions containing the same and methods for using them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| EP-2294051-B1 | ALPHA-SUBSTITUTED N-SULFONYL GYLCINE AMIDES ANTAGONISTS OF CCR10, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR USING THEM | BOEHRINGER INGELHEIM INT (DE) | 2014-08-13 | — | — | EP | disclosed |
| US-20120258963-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2012-10-11 | — | — | US | disclosed |
| US-5015641-A | Dipeptide for vision defects | ANDREWS DAVID R (US) | 1991-05-14 | — | — | US | disclosed |
| US-4885293-A | CARBOXYALKYL DIPEPTIDES | SCHERING CORPORATION (US) | 1989-12-05 | — | — | US | disclosed |
| EP-0195817-B1 | CARBOXYALKYLDIPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1989-10-18 | — | — | EP | disclosed |
| US-4826816-A | Antihypertensive compounds | SCHERING CORPORATION (US) | 1989-05-02 | — | — | US | disclosed |
| US-4328363-A | Manufacture of gamma halogen substituted adducts | MOBIL OIL CORPORATION (US) | 1982-05-04 | — | — | US | disclosed |
| US-4119646-A | Hexahydrobenzofuranone compounds | MOBIL OIL CORPORATION (US) | 1978-10-10 | — | — | US | disclosed |
| US-4087549-A | Sulphonic acid containing indenyl derivatives | MERCK & CO., INC. (US) | 1978-05-02 | — | — | US | disclosed |
| US-4011239-A | MANGANESE, VANADIUM, CERIUM | MOBIL OIL CORPORATION (US) | 1977-03-08 | — | — | US | disclosed |
| US-3996164-A | FROM COBALT CARBONYL AND A PYRIDINE | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JA) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258963-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | CYP3A4 321/4885CYP1A2 152/4885SLC6A3 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.